3 results
Approved WMOCompleted
*To evaluate the safety and tolerability of RO7009789 and vanucizumab when administered in combination* To determine the maximum tolerated dose (MTD) (for the SC administration and potentially for the IV), route and recommended Phase II dose of…
Approved WMOPending
The primary objective of the study is to assess the pharmacokinetics (PK) of PXL770 in AMN subjects at the dose of 500mg once daily (OD) and 250mg twice daily (BID) after 4 weeks of treatment.
Approved WMOCompleted
The main objectives of this study are to determine the accuracy of the device (1) to determine functional oxygen saturation (SpO2) compared to a reference device, and (2) to determine respiratory rate compared to visual observations. As a secondary…